Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05252585 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05252585 · ClinicalTrials.gov record · last posted 2026-06-11

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Name: A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) — clinical trial record (NCT05252585)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 4

SponsorNovartis Pharmaceuticals

Started2023-05-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) . Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.

Protocol amendment history 2 changes detected by DataLookout

2026-04-03

Primary completion moved earlier: 2026-11-25 → 2026-10-10

2026-04-03

Completion moved earlier: 2026-11-25 → 2026-10-10

Trial Details

NCT Number	NCT05252585
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Renal Angiomyolipoma
Enrollment	4 participants
Start Date	2023-05-01
Primary Completion	2026-10-10 (estimated)
Study Completion	2026-10-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-11